Devita, Hellman, and Rosenberg's Cancer

LWBK1006-42 LWW-Govindan-Review December 12, 2011 20:38

Chapter 42•Stem Cell Transplantation 529

Question 42.21. Limitations of autologous SCT, compared with allogeneic SCT, include

all of the following, EXCEPT:

A. Lack of potential graft-versus-tumor effect

B. Higher treatment-related mortality

C. Potential graft contamination with tumor cells

D. Higher relapse risk

Question 42.22. Factors that influence the choice of conditioning regimen include:

A. Underlying malignancy and prior treatment

B. Patient age and comorbidity

C. Donor:recipient HLA compatibility

D. All of the above

Question 42.23. Potential benefits of reduced-intensity conditioning regimens for allo-

geneic SCT include all of the following, EXCEPT:

A. Decreased period of neutropenia

B. Improved tumor cytoreduction

C. Decreased regimen-related toxicity

D. Appropriate for older patients or with significant comorbidity

Question 42.24. Evidence supporting the existence of the graft-versus-tumor effect

includes the following, EXCEPT:

A. Decreased relapse risk among patients with acute and chronic GVHD

B. Increased relapse risk among recipients of identical twin donor grafts

C. Decreased relapse risk among recipients of T-depleted grafts

D. Spontaneous remission after posttransplant relapse on tapering of

immunosuppression

Question 42.25. Late complications after allogeneic SCT include:

A. Skeletal complications, including osteoporosis and avascular necrosis

B. Secondary malignancies

C. Endocrine failure

D. All of the above

Question 42.26. Risk factors for acute GVHD includes the following, EXCEPT:

A. Increased age

B. Graft T-cell depletion

C. Donor:recipient HLA disparity

D. Inadequate GVHD prophylaxis

Question 42.27. What is the most common cause of late hemorrhagic cystitis in patients

undergoing allogeneic SCT?

A. Cyclophosphamide

B. BK virus

C. Adenovirus

D. B and C